Class Action Announcement for DexCom, Inc. (DXCM): Kessler Topaz Meltzer & Check, LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against DexCom, Inc.

Core Viewpoint - A securities class action lawsuit has been filed against DexCom, Inc. for alleged misleading statements and undisclosed material changes to its glucose monitoring systems during the specified Class Period [1][2]. Allegations Against DexCom - The lawsuit claims that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [2]. - It is alleged that DexCom overstated the enhancements and reliability of the G7 device, downplaying the severity of issues related to the adulterated devices [2]. - The complaint suggests that these actions increased the risk of regulatory scrutiny and potential legal, reputational, and financial harm to DexCom [2]. Lead Plaintiff Process - Investors in DexCom have until December 26, 2025, to seek appointment as a lead plaintiff, representing the interests of the class in the litigation [3]. - The lead plaintiff is typically the investor or group of investors with the largest financial stake and who are representative of the class [3]. Contact Information - Kessler Topaz Meltzer & Check, LLP encourages affected DexCom investors to reach out for more information regarding the lawsuit [4].